

# CooperCompanies

## Fiscal 2024 & Q4'24 financial guidance

		FY24 Guidance*	Q4 2024 Guidance
Sales	Total	\$3,892 - \$3,913 (8% - 8.5% organic growth)	\$1,015 - \$1,036 (7% - 9.5% organic growth)
	CooperVision	\$2,606 - \$2,618 (9% - 9.5% organic growth)	\$673 - \$685 (8% - 10% organic growth)
	CooperSurgical	\$1,286 - \$1,294 (5.5% - 6.5% organic growth)	\$342 - \$350 (6% - 8% organic growth)
EPS	Non-GAAP	\$3.64 - \$3.67	\$0.98 - \$1.01

Notes: Sales \$ in millions

Organic growth excludes the effect of foreign currency fluctuations and the impact of any acquisitions, divestitures, or discontinuations that occurred in the comparable period. A reconciliation of non-GAAP measures are available under the "Reconciliation of Selected GAAP Results to Non-GAAP Results" section in our earning releases and under the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, copies of which are available on our website: [www.coopercos.com](http://www.coopercos.com). With respect to EPS guidance, the Company has not provided reconciliation to GAAP due to the inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses. Due to the unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share, we are not able to provide such guidance.

\*Guidance raised 8/28/24.

